Moderna (NASDAQ:MRNA) CFO James Mock Sells 34,836 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) CFO James Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Moderna Trading Up 1.9%

NASDAQ MRNA traded up $2.72 during trading on Monday, hitting $146.69. 10,538,519 shares of the company’s stock traded hands, compared to its average volume of 11,614,295. The stock has a fifty day moving average of $92.35 and a two-hundred day moving average of $66.85. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The firm has a market cap of $58.56 billion, a P/E ratio of -18.36 and a beta of 1.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the previous year, the business earned ($2.13) earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -6.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. William Blair initiated coverage on shares of Moderna in a research report on Friday, August 28th. They issued an “outperform” rating on the stock. CLSA raised shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Moderna in a research note on Friday, August 28th. They issued a “hold” rating on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a report on Friday, August 21st. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $76.72.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. TD Waterhouse Canada Inc. boosted its position in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after purchasing an additional 85 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares in the last quarter. New Mexico Educational Retirement Board raised its holdings in shares of Moderna by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after purchasing an additional 300 shares in the last quarter. IFP Advisors Inc lifted its stake in Moderna by 5.4% during the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after purchasing an additional 348 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its stake in Moderna by 16.9% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after purchasing an additional 382 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.